On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Friday, December 02, 2011

Serious Adverse Events (SAE) vs Severe Adverse Events

›
Professionals who are new to the clinical trial field are often confused with the concept of ' Serious Adverse Events (SAEs)' and ...
Sunday, November 27, 2011

Reporting/recording the Serious Adverse Events (SAE) vs. Adverse Event (AE) Outcomes

›
In clinical trials, the serious adverse event reporting is critical to the safety assessment and to fulfill the regulatory requirements. The...
1 comment:
Thursday, November 24, 2011

Studentized residual for detecting outliers

›
Last time, I discussed the outliers and a simple approach of Dixon’s Q test for detecting a single outlier . When there are multiple outlier...
Saturday, November 12, 2011

Outliers in clinical trial, Dixon's Q test for a single outlier

›
In clinical trials, we deal with the outlier issue differently from other fields. During the clinical trial, for the suspected ‘outlier...
Saturday, October 29, 2011

Story of Xigris (Protein C) for Sepsis

›
Xigris , also called Drotrecogin Alfa (Activated) or Protein C, was the only approved drug for severe sepsis indication and it was withdraw...
Thursday, October 27, 2011

A medical joke to share

›
Not sure where the origin is. It is circulated quite a bit.  Best friends graduated from medical school at the same time and decided that, ...
1 comment:
Saturday, October 15, 2011

Will Electronic Data Capture be always better than Paper-CRF?

›
The traditional way to do the clinical trial data management is to use the paper based case report forms (CRFs). The blank paper CRFs are di...
Tuesday, September 13, 2011

Confidence Interval for Difference in Two Proportions

›
In many clinical trials, the outcome is binomial and a 2 x 2 table can be constructed. The analysis can be based on the difference in two ...
1 comment:
Friday, September 09, 2011

Is it time to change the clinical monitoring practice in clinical trials?

›
In industry, the current monitoring practice relies on ‘ on-site monitoring ’ and 100% source data verification (on all data fields). This ...
2 comments:
Sunday, August 21, 2011

Odds ratio and risk ratio in clinical trials #2

›
In my previous article, I discussed the odds ratio and risk ratio (or relative risk ratio) . In clinical trials with binary outcome, both ...
Thursday, August 18, 2011

FDA's new guidance on device approval process and device clinical trial

›
For a long time, device makers have been complaining about the FDA's device approval process . I personally heard a lot of talks that th...
4 comments:
Saturday, August 13, 2011

Equipoise and Lack of Equipoise in Randomized Clinical Trials

›
According to Merriam-Webster dictionary, the word " Equipoise " means a state of equilibrium. In clinical trial, the concept of ...
1 comment:
Thursday, July 14, 2011

Data Query on Diary and Patient Reported Outcome?

›
We keep hearing that for patient report outcome (PRO) including patient diary data, there is no query or data clarification required and the...
Thursday, July 07, 2011

Adaptive Licensing for Drug Approval

›
From this year’s Drug Information Association (DIA) annual conference in Chicago, I learned a new concept of “Adaptive Licensing”. Accordin...
Saturday, June 18, 2011

Is blinded study really blinded? - assessment of blinding / unblinding in clinical trials

›
Randomization and blinding are critical components of the clinical trial from the start (design) to the end. Randomized, controlled, and ...
1 comment:
Wednesday, June 15, 2011

Bland-Altman Plot for Assessing Agreement

›
Bland-Altman plot is a scatter plot of variable means plotted on the horizontal axis and the differences plotted on the vertical axis wh...
2 comments:
Friday, June 03, 2011

Restructure FDA's Drug Review Process?

›
Last week, I had a chance to listen to a speech by Dr Scott Gottlieb. While he touched several topics in related to the health care refor...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.